ArriVent CFO granted option on 140,000 shares

ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4.

Rhea-AI Filing Summary

ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4. On February 2, 2026, he was awarded an option to purchase 140,000 shares of common stock at an exercise price of $22.67 per share.

The option vests over time, with 25% of the underlying shares vesting on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on his continued service with the company through each vesting date. The option expires on February 2, 2036.

Insider Trade Summary

Grant/Award: 140,000 shares

Grant/Award 1 txn

Insider Kung Winston

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	140,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 140,000 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ArriVent BioPharma (AVBP) report for Winston Kung?

ArriVent BioPharma reported a stock option grant to CFO Winston Kung. He received an option for 140,000 shares of common stock on February 2, 2026, as part of his compensation, with a long-term vesting schedule tied to continued service.

How many ArriVent BioPharma (AVBP) shares are covered by Winston Kung’s new option?

The option granted to Winston Kung covers 140,000 shares of ArriVent BioPharma common stock. These shares are not issued immediately; they become exercisable over time as the option vests according to the specified schedule and service conditions.

What is the exercise price of Winston Kung’s ArriVent BioPharma (AVBP) stock option?

The stock option has an exercise price of $22.67 per share. This means Kung can purchase ArriVent BioPharma common stock at $22.67 once the option vests, provided he remains in service through the relevant vesting dates.

When does Winston Kung’s ArriVent BioPharma (AVBP) option start vesting?

The option begins vesting on February 2, 2027, when 25% of the shares vest. The remaining 75% vests in 36 equal monthly installments after that date, subject to his continued service with ArriVent BioPharma.

What is the full vesting schedule for Winston Kung’s AVBP stock option?

First, 25% of the 140,000 underlying shares vest on February 2, 2027. The remaining 75% then vests in 36 equal monthly installments, so portions vest each month, assuming Kung continues to serve the company throughout this period.

When does Winston Kung’s ArriVent BioPharma (AVBP) stock option expire?

The stock option expires on February 2, 2036. After that expiration date, any unexercised portion of the option becomes invalid, so exercises must occur before then, and only for shares that have already vested.

Is Winston Kung’s ArriVent BioPharma (AVBP) stock option held directly or indirectly?

The filing shows Winston Kung holds the option directly, marked with ownership type “D.” There is no indication in the provided footnote of any trust, LLC, or other entity holding the option on his behalf.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/04/2026 - 08:41 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kung Winston

(Last) (First) (Middle)

C/O ARRIVENT BIOPHARMA, INC.

18 CAMPUS BOULEVARD, SUITE 100

(Street)

NEWTOWN SQUARE PA 19073

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ArriVent BioPharma, Inc. [ AVBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$22.67	02/02/2026		A		140,000		(1)	02/02/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ James Kastenmayer, Attorney-in-Fact for Winston Kung	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.